Data doesn't support nod for BioMarin's muscle-wasting drug: FDA staff

November 20, 2015 2:12 PM

22 0

U.S. Food and Drug Administration staff reviewers said clinical data to date did not merit approving BioMarin Pharmaceutical Inc's muscle-wasting disorder drug.

The FDA staff reviewers raised questions over the clinical benefit of the drug, drisapersen, and said long-term data submitted by BioMarin did not support an approval at this time.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page